59467-96-8

Usage

Uses

Different sources of media describe the Uses of 59467-96-8 differently. You can refer to the following data:
1. Anti-Spasmodic
2. Midazolam Hydrochloride is a sensitive CYP 3A4 probe substrate.

Biological Activity

Sedative/hypnotic agent that acts at the GABA A receptor benzodiazepine modulatory site.

Veterinary Drugs and Treatments

In veterinary patients, midazolam is used principally as a premedicant for general anesthesia. Alone, it does not appear to provide predictable sedation in animals. Animals may become sedated or dysphoric and excited. Cats may be more prone to develop the “excited” effect more than dogs. When used in combination with other drugs (i.e., opioids or ketamine), midazolam does provide more predictable sedation. Midazolam may also be of benefit to treat status epilepticus when given either IV or IM (not rectally). In humans, midazolam has been suggested for use as a premedicant before surgery, and as a conscious sedative when combined with potent analgesic/anesthetic drugs (e.g., ketamine or fentanyl). In humans, midazolam reduces the incidences of “dreamlike” emergence reactions and increases in blood pressure and cardiac rate caused by ketamine. When compared to the thiobarbiturate induction agents (e.g., thiamylal, thiopental), midazolam has less cardiopulmonary depressant effects, is water-soluble, can be mixed with several other agents, and does not tend to accumulate in the body after repeated doses.

InChI:InChI=1/C18H13ClFN3.ClH/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13;/h2-9H,10H2,1H3;1H

Upstream product

• 59467-70-8 Midazolam 
• 59468-44-9 8-Chloro-6-(2-fluorophenyl)-1-methyl-4H-imidazo[1,5-a][1,4]benzodiazepine-3-carboxylic acid 

Relevant academic research and scientific papers

Preparation method and application of midazolam hydrochloride F crystal form

The invention discloses a preparation method and application of a novel midazolam hydrochloride crystal form, and gives the X-ray powder diffraction characteristic value of the crystal form. The disclosed novel midazolam hydrochloride crystal form is name

THERAPEUTIC COMPOUNDS AND FORMULATIONS FOR INTRANASAL DELIVERY

Certain embodiments of the invention provide a formulation suitable for nasal administration comprising water, a prodrug of a therapeutic agent, and an enzyme that is suitable for intranasal conversion of the prodrug to the therapeutic agent, as well as methods of use thereof.

PROCESS FOR THE SYNTHESIS OF 4H-IMIDAZO [1,5-a] [1,4] BENZODIAZEPINES, IN PARTICULAR MIDAZOLAM AND SALTS THEREOF

The present invention refers to a process for the preparation of 4H-imidazo[1,5-a][1,4]benzodiazepines, in particular Midazolam, through an efficient and selective decarboxylation reaction of the derivative compound of the 5-aminomethyl-1-phenyl-1H-imidazole-4-carboxylic acid of formula (II) avoiding the formation of the 6H-imidazo[1,5-a][1,4]benzodiazepines by-products and the ensuing process for the isomerisation of a 4H-imidazo[1,5-a][1,4]benzodiazepine product.

Process for the synthesis of 4H-imidazo[1,5-a][1,4]benzodiazepines, in particular midazolam and salts thereof

The present invention refers to a process for the preparation of 4H-imidazo[1,5-a] [1,4]benzodiazepines, in particular Midazolam, through an efficient and selective decarboxylation reaction of the derivative compound of the 5-aminomethyl-1-phenyl-1H-imidazole-4-carboxylic acid of formula (II) avoiding the formation of the 6H-imidazo[1,5-a][1,4]benzodiazepines by-products and the ensuing process for the isomerisation of a 4H-imidazo[1,5-a][1,4]benzodiazepine product.

Imidazodiazepines and processes therefor

Novel Imidazobenzodiazepines and their analogs are useful as anticonvulsants, muscle relaxant, anxiolytic and sedative agents. Preferred compounds of this class belong to the imidazo[1,5-a][1,4]diazepine series which may have a very wide variety of organic substituents. An especially preferred genus included within the purview of the invention encompasses a compound of the formula STR1 wherein R1 is hydrogen and lower alkyl preferably methyl; R3 and R5 are hydrogen; R4 is hydrogen, nitro and halogen, most preferably, chlorine, and in a most preferred embodiment when positioned on the fused benzo portion of the imidazobenzodiazepine is in the 8-position thereof, R6 is phenyl or halo, nitro, or lower alkyl-substituted phenyl, preferably, halo, with fluorine being the preferred halogen, the substituted fluoro being positioned in the 2-position of the phenyl moiety and R2 is hydrogen and lower alkyl.